西部中医药
西部中醫藥
서부중의약
GANSU JOURNAL OF TRADITIONAL CHINESE MEDICINE
2015年
1期
78-80
,共3页
溃疡性结肠炎%肠安康胶囊%美沙拉嗪
潰瘍性結腸炎%腸安康膠囊%美沙拉嗪
궤양성결장염%장안강효낭%미사랍진
ChangAnKangCapsule%mesalazine%ulcerative colitis
目的:观察肠安康胶囊联合美沙拉嗪治疗溃疡性结肠炎的临床疗效。方法:将溃疡性结肠炎患者60例随机分为2组各30例,对照组使用美沙拉嗪肠溶片治疗,3次/d,0.5 g/次,观察组在对照组治疗的基础上使用肠安康胶囊4.4 g/d,2组均连续治疗1个月后观察治疗前后SOD和GSH-PX变化情况及患者临床症状改善时间,并在治疗后1月实施肠镜检查,观察治疗后肠镜等级。结果:治疗后观察组SOD和GSH-PX均高于对照组(P<0.05);观察组腹痛腹胀、便血、里急后重及腹泻改善时间快于对照组(P<0.05);观察组肠镜复查等级在Ⅱ级及以下的比例高于对照组(P<0.05)。结论:肠安康胶囊联合美沙拉嗪治疗溃疡性结肠炎,能有效抑制氧自由基对机体的损伤,缓解患者临床症状,提高治疗效果。
目的:觀察腸安康膠囊聯閤美沙拉嗪治療潰瘍性結腸炎的臨床療效。方法:將潰瘍性結腸炎患者60例隨機分為2組各30例,對照組使用美沙拉嗪腸溶片治療,3次/d,0.5 g/次,觀察組在對照組治療的基礎上使用腸安康膠囊4.4 g/d,2組均連續治療1箇月後觀察治療前後SOD和GSH-PX變化情況及患者臨床癥狀改善時間,併在治療後1月實施腸鏡檢查,觀察治療後腸鏡等級。結果:治療後觀察組SOD和GSH-PX均高于對照組(P<0.05);觀察組腹痛腹脹、便血、裏急後重及腹瀉改善時間快于對照組(P<0.05);觀察組腸鏡複查等級在Ⅱ級及以下的比例高于對照組(P<0.05)。結論:腸安康膠囊聯閤美沙拉嗪治療潰瘍性結腸炎,能有效抑製氧自由基對機體的損傷,緩解患者臨床癥狀,提高治療效果。
목적:관찰장안강효낭연합미사랍진치료궤양성결장염적림상료효。방법:장궤양성결장염환자60례수궤분위2조각30례,대조조사용미사랍진장용편치료,3차/d,0.5 g/차,관찰조재대조조치료적기출상사용장안강효낭4.4 g/d,2조균련속치료1개월후관찰치료전후SOD화GSH-PX변화정황급환자림상증상개선시간,병재치료후1월실시장경검사,관찰치료후장경등급。결과:치료후관찰조SOD화GSH-PX균고우대조조(P<0.05);관찰조복통복창、편혈、리급후중급복사개선시간쾌우대조조(P<0.05);관찰조장경복사등급재Ⅱ급급이하적비례고우대조조(P<0.05)。결론:장안강효낭연합미사랍진치료궤양성결장염,능유효억제양자유기대궤체적손상,완해환자림상증상,제고치료효과。
Objective: To investigate the effect of ChangAnKangCapsule combined with mesalazine on the treatment of ulcerative colitis. Methods: Overall 60 cases with ulcerative colitis were randomly divided into the con-trol group and the observation group with 30 cases respectively. Patients in the control group were given mesalazine enteric-coated tablets, 3 times a day, 0.5g each time; besides taking mesalazine like patients in the control group, pa-tients in the observation group were administered ChangAnKang Capsule 4.4g a day. After one month treatment, the changes of SOD and GSH-PX levels as well as the time the clinical symptoms improved were compared before and after treatment in both groups; meanwhile, the ulcer degrees observed by colonoscopy would be presented in two groups. Results: The levels of SOD and GSH-PX in the observation group were higher than that in the control group (P<0.05); the improved time of symptoms like abdominal pain and distention, hematochezia, tenesmus and diarrhea in the observation group was faster than that in the control group (P<0.05); the ulcer degrees in and belowⅡlevel determined by colonoscopy in the observation group were more than the control group (P<0.05). Conclusion: The integration ofChangAnKangCapsule and mesalazine in treating ulcerative colitis can effectively inhibit the body im-pairment from oxygen free radicals, relieve clinical symptoms and improve the therapeutic effect.